|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The TMPRSS2-ERG positive status correlates with moderate to poorly differentiated prostate tumors and it is considered as unfavorable disease predictor.
|
25753984 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
|
18483239 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results provide supportive evidence that androgen signaling underlies the development of prostate tumors that harbor TMPRSS2:ERG.
|
24925673 |
2014 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
TMPRSS2-ERG (T2E) structural rearrangements typify ∼50% of prostate tumors and result in overexpression of the ERG transcription factor.
|
28783165 |
2017 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We have quantitatively analyzed the mRNA levels of TMPRSS2-ERG, ERG, PTEN, and AR (n = 83), as well as ERG immunostaining (n = 78) in a series of prostate tumors.
|
25939480 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.
|
19597533 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In human CaP, gene fusion between androgen responsive regulatory elements at the 5'-untranslated region of TMPRSS2 and ETS-related genes (ERG) is present in at least 50% of prostate tumors.
|
31303963 |
2019 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
|
16820092 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype.
|
27753122 |
2017 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth.
|
25088707 |
2014 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.
|
28598696 |
2017 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
|
16585160 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
|
18519769 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
TMPRSS2 genetic alterations detectable by this method are strictly restricted in prostate neoplasia, and can be identified in the majority of prostate carcinomas.
|
20736744 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ets related gene (ERG) is a transcription factor that is overexpressed in 40% of prostate tumors due to a gene fusion between ERG and TMPRSS2.
|
27626314 |
2016 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A consequence of autocatalytic cleavage is the secretion of the protease domain into the media by TMPRSS2-expressing prostate cancer cells and into the sera of prostate tumor-bearing mice.
|
11245484 |
2001 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion.
|
17584912 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
|
17654723 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
|
18694509 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
TMPRSS2-ERG gene fusions found in human prostate tumors are a hallmark of chromoplexy.
|
26751641 |
2016 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells.
|
18385909 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Integrative molecular profiling of routine clinical prostate cancer specimens.
|
25735316 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
|
17632455 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recently, it was shown that up to 80% of prostate tumours harbour at least one such gene fusion, and that the most common fusion event, between the prostate-specific TMPRSS2 gene and the ERG oncogene, is a critical, and probably early factor in prostate cancer development.
|
23535644 |
2013 |